Oral 4 – Results of First Round of Enrollment from the Screening for Pancreatic Cancer in High-Risk Individuals (Pancreas Scan Study): A Prospective Multi-Center Study
Monday, October 24, 2022 | 8:36 AM – 8:48 AM ET | Location: Hall C2
Author Insight from Andy Silva-Santisteban, MD, Beth Israel Deaconess Medical Center, Harvard Medical School
What’s new here and important for clinicians?
We prospectively enrolled 252 consecutive patients who underwent pancreatic cancer screening at five centers across the United States. The yield of pancreatic cancer screening for high-risk lesions like pancreatic cancer was 0.8%, which is at the lower end of the range that has been reported in the literature16. No patient in our study was diagnosed with high grade-dysplasia or high-grade PanIN. The yield of screening for intermediate-risk pancreatic lesions was 31.7%, almost all branch duct IPMNs without worrisome features. No harms of pancreatic cancer screening were noted. No patient in our study underwent low-yield pancreatic cancer surgery, a much lower proportion than reported in the literature18. In patients undergoing screening, new-onset prediabetes was noted in 18.2%, and new-onset diabetes was noted in 1.7%. There was no association between abnormal blood sugars and pancreas pathology.
What do patients need to know?
Patients should be carefully counselled regarding benefits and harms from pancreatic cancer screening. When feasible, such screening should be performed within the confines of a research study so more precise estimates of screening outcomes can be determined.
Read the Abstract
Andy Silva-Santisteban, MD, Beth Israel Deaconess Medical Center, Harvard Medical School
asantist [at] bidmc.harvard.edu
Media Interview Requests
To arrange an interview with any ACG experts or abstract authors, please contact Becky Abel of ACG via email at mediaonly [at] gi.org or by phone at 301-263-9000.